Development of detecting assay for anti-myelin oligodendrocyte glycoprotein antibody
Project/Area Number |
20K07892
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Review Section |
Basic Section 52020:Neurology-related
|
Research Institution | Tohoku Medical and Pharmaceutical University |
Principal Investigator |
|
Project Period (FY) |
2020-04-01 – 2023-03-31
|
Project Status |
Completed (Fiscal Year 2022)
|
Budget Amount *help |
¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2022: ¥390,000 (Direct Cost: ¥300,000、Indirect Cost: ¥90,000)
Fiscal Year 2021: ¥390,000 (Direct Cost: ¥300,000、Indirect Cost: ¥90,000)
Fiscal Year 2020: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
|
Keywords | 脱髄疾患 / 自己抗体 / 検査法 / MOG抗体関連疾患 / 多発性硬化症 / 視神経脊髄炎 |
Outline of Research at the Start |
近年、中枢神経の炎症性脱髄疾患の中に抗ミエリンオリゴデンドロサイト糖蛋白(MOG)抗体が関与する病態が存在することが明らかになってきており、多発性硬化症や視神経脊髄炎とは異なる新たな疾患概念として確立しつつある。診断には抗MOG抗体の測定が必須であるが、現在の測定法は煩雑かつコストが高く、検査の普及を妨げており、保険適用に至っていない。本研究は診断マーカーとしての抗MOG抗体の新たな測定法の開発を目的とする。
|
Outline of Final Research Achievements |
It is becoming clear that myelin oligodendrocyte glycoprotein (MOG) antibodies are involved in inflammatory demyelinating diseases of the central nervous system, and this is being established as a new disease concept distinct from multiple sclerosis and neuromyelitis optica. Measurement of MOG antibodies is essential for diagnosis, but the current measurement method is complicated and costly, preventing widespread use of the test, and has not yet been covered by insurance. In this study, we developed a new assay for MOG antibodies as a diagnostic marker and analyzed the clinical significance of MOG antibodies in relation to cytokines and other substances in serum and cerebrospinal fluid while conducting a nationwide epidemiological survey.
|
Academic Significance and Societal Importance of the Research Achievements |
MOG抗体関連疾患はMOGADとよばれ、当科において初の全国疫学調査を実施した。これにより全国に1700人程度の患者が存在していることがあきらかになった。また、国際的なMOGADの診断基準が提唱され、今後独立した疾患概念として確立していく疾患である。一方でMOG抗体の測定は保険適用になっておらず、測定法のキット化が必要であり、感度および特異度の高い検査法の確立が求められている。今回の研究により開発を進めているMOG抗体測定法を今後キット化することにより、疾患の診断が容易になるため、臨床的な意義が大きい。
|
Report
(4 results)
Research Products
(23 results)
-
-
-
-
-
[Journal Article] GRP78 Antibodies Are Associated With Blood-Brain Barrier Breakdown in Anti-Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorder2021
Author(s)
Shimizu F, Ogawa R, Mizukami Y, Watanabe K, Hara K, Kadono C, Takahashi T, Misu T, Takeshita Y, Sano Y, Fujisawa M, Maeda T, Nakashima I, Fujihara K, Kanda T.
-
Journal Title
Neurol Neuroimmunol Neuroinflamm
Volume: 9
Issue: 1
DOI
Related Report
Peer Reviewed / Open Access
-
-
[Journal Article] Difference in the Source of Anti-AQP4-IgG and Anti-MOG-IgG Antibodies in CSF in Patients With Neuromyelitis Optica Spectrum Disorder.2021
Author(s)
Akaishi T, Takahashi T, Misu T, Kaneko K, Takai Y, Nishiyama S, Ogawa R, Fujimori J, Ishii T, Aoki M, Fujihara K, Nakashima I.
-
Journal Title
Neurology.
Volume: 97
Issue: 1
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Five-year visual outcomes after optic neuritis in anti-MOG antibody-associated disease.2021
Author(s)
Akaishi T, Himori N, Takeshita T, Misu T, Takahashi T, Takai Y, Nishiyama S, Fujimori J, Ishii T, Aoki M, Fujihara K, Nakazawa T, Nakashima I.
-
Journal Title
Mult Scler Relat Disord
Volume: 56
Pages: 103222-103222
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Myelin oligodendrocyte glycoprotein-IgG-positive, steroid-responsive combined central and peripheral demyelination with recurrent peripheral neuropathy.2021
Author(s)
Nakamura T, Kaneko K, Watanabe G, Harashima S, Kawasaki E, Tsukita K, Takahashi T, Nakashima I, Misu T, Suzuki Y.
-
Journal Title
Neurol Sci
Volume: 42
Issue: 3
Pages: 1135-1138
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
-
-
-
[Journal Article] Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study2020
Author(s)
Takai Y, Misu T, Kaneko K, Chihara N, Narikawa K, Tsuchida S, Nishida H, Komori T, Seki M, Komatsu T, Nakamagoe K, Ikeda T, Yoshida M, Takahashi T, Ono H, Nishiyama S, Kuroda H, Nakashima I, Suzuki H, Bradl M, Lassmann H, Fujihara K, Aoki M
-
Journal Title
Brain
Volume: 143
Issue: 5
Pages: 1431-1446
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
[Journal Article] CSF levels of glutamine synthetase and GFAP to explore astrocytic damage in seronegative NMOSD2020
Author(s)
Kleerekooper I, Herbert MK, Kuiperij HB, Sato DK, Fujihara K, Callegaro D, Marignier R, Saiz A, Senel M, Tumani H, de Jong BA, Trip SA, Nakashima I, Verbeek MM, Petzold A
-
Journal Title
J Neurol Neurosurg Psychiatry
Volume: 91
Issue: 6
Pages: 605-611
DOI
Related Report
Peer Reviewed / Int'l Joint Research
-
-
-
-
[Journal Article] Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients.2020
Author(s)
Whittam DH, Cobo-Calvo A, Lopez-Chiriboga AS, Pardo S, E, Ciron J, Deschamps R, Biotti D, Rostasy K, Neuteboom R, HemingwaGornall M, Cicconi S, Brandt A, Berek K, Berger T, Jelcic I, Gombolay G, Oliveira LM, Callegaro D, Kaneko K, Misu T, et al.
-
Journal Title
Mult Scler Relat Disord
Volume: 44
Pages: 102251-102251
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
-
-